| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/12/2005 | CA2460873A1 Inhibitors of siderophore biosynthesis in fungi |
| 09/09/2005 | WO2005083076A1 Immune stimulant oligonucleotide inducing interferon alpha |
| 09/09/2005 | WO2005082889A1 Piperidinyl targeting compounds that selectively bind integrins |
| 09/09/2005 | WO2005082887A1 Pyrimidine derivative |
| 09/09/2005 | WO2005082422A1 Combination of ad-p53 and chemotherapy for the treatment of tumours |
| 09/09/2005 | WO2005082415A2 Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth |
| 09/09/2005 | WO2005082414A2 Concomitant drugs of a sulfonamide and another therapeutic agent |
| 09/09/2005 | WO2005082412A1 Drug for treating and preventing cancer |
| 09/09/2005 | WO2005082397A1 Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor |
| 09/09/2005 | WO2005082389A1 Cancer metastasis inhibitory composition |
| 09/09/2005 | WO2005082386A2 Manganese and iron based compounds for elastogenesis and connective tissue treatment |
| 09/09/2005 | WO2005082385A1 Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions |
| 09/09/2005 | WO2005082383A1 A medical solution, a method for producing said medical solution and use thereof |
| 09/09/2005 | WO2005082372A1 COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS |
| 09/09/2005 | WO2005082364A1 Compositions comprising hiv protease inhibitor and cytochrome p450 enzyme activity inhibitor |
| 09/09/2005 | WO2005082362A1 Therapeutic combinations |
| 09/09/2005 | WO2005082329A2 Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide |
| 09/09/2005 | WO2005081870A2 Intervertebral disc repair, methods and devices therefor |
| 09/09/2005 | WO2005060976A3 Use of superoxide dismutase mimetics and reductase glutathione in the form of anticancer drugs |
| 09/09/2005 | WO2005044243A8 Transdermal analgesic systems having reduced abuse potential |
| 09/09/2005 | WO2005044192A3 Triazole compounds and uses related thereto |
| 09/09/2005 | WO2005042714A3 Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| 09/09/2005 | WO2005027973A3 Combinations of a vegf receptor inhibitor with other therapeutic agents |
| 09/09/2005 | WO2005016271A3 Composition comprising a zeolite compound for treatment of diseases |
| 09/09/2005 | WO2005014584A8 3-(indol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones,3-(benzimidazol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones, and 3-(indolin-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones; their preparation and use as modulators of apoptosis |
| 09/09/2005 | WO2004112763A3 Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure |
| 09/09/2005 | WO2004100879A3 Method and composition for preventing or reducing edema, deep vein thrombosis and/or pulmonary embolism |
| 09/09/2005 | WO2004096144A3 Compositions and methods for induction of opioid receptors |
| 09/09/2005 | WO2004080482A8 Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure |
| 09/09/2005 | WO2004064777A3 Modified polysaccharides combination with anti-cancer drugs for enhanced treatment of cancer |
| 09/09/2005 | CA2846382A1 Iron based compounds for elastogenesis and connective tissue treatment |
| 09/09/2005 | CA2562871A1 Iron based compounds for elastogenesis and connective tissue treatment |
| 09/09/2005 | CA2557541A1 Pyrimidine derivatives |
| 09/09/2005 | CA2557504A1 Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor |
| 09/09/2005 | CA2557326A1 Combination of ad-p53 and chemotherapy for the treatment of tumours |
| 09/09/2005 | CA2556832A1 Binding peptidomimetics and uses of the same |
| 09/09/2005 | CA2556768A1 Piperidinyl targeting compounds that selectively bind integrins |
| 09/09/2005 | CA2555173A1 Compositions comprising hiv protease inhibitor and cytochrome p450 enzyme activity inhibitor |
| 09/09/2005 | CA2555171A1 Therapeutic combinations |
| 09/09/2005 | CA2553291A1 Combination of .gamma.-aminobutyric acid modulators and 5-ht1b receptor antagonists |
| 09/09/2005 | CA2548771A1 A medical solution, a method for producing said medical solution and use thereof |
| 09/08/2005 | US20050197399 Method of augmenting the antitumor activity of anticancer agents |
| 09/08/2005 | US20050197397 Method and composition for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite |
| 09/08/2005 | US20050197376 Concomitant drugs |
| 09/08/2005 | US20050197375 Use of benzimidazole analogs in the treatment of cell proliferation |
| 09/08/2005 | US20050197372 Use of valsartan or its metabolite to inhibit platelet aggregation |
| 09/08/2005 | US20050197349 Pyrrolo[2,3-D]pyrimidine compounds |
| 09/08/2005 | US20050197332 Synergistic inhibition of aggregation and inflammation in vessel walls |
| 09/08/2005 | US20050197323 Full or partial glucocorticosteroid replacement therapy for obstructive pulmonary bronchial diseases |
| 09/08/2005 | US20050197316 Method of enhancing drainage of lacrimal system with purinergic receptor agonists |
| 09/08/2005 | US20050197300 Microdose therapy |
| 09/08/2005 | US20050197299 Peptidomimetic protease inhibitors |
| 09/08/2005 | US20050197291 Administering compound which blocks endothelial growth factor |
| 09/08/2005 | US20050197283 Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease |
| 09/08/2005 | US20050196838 Reduced immunogenicity; increased affinity and avidity; improved cell culturing |
| 09/08/2005 | US20050196802 peptide of given amino acid sequence related to the sulfotransferase drug-metabolizing enzyme subfamily; use drug screening |
| 09/08/2005 | US20050196797 PI-3-kinase-related kinase polypeptide for use as tool in identifying modulators for prevntion and treatment of cell proliferation disorders |
| 09/08/2005 | US20050196793 Using aberrant expression of caudal type homeobox transcription factor 2 (CDX2) as diagnostic indicator of stomach or esophageal cell proliferative disorers |
| 09/08/2005 | US20050196466 Process for inhibiting cell proliferation |
| 09/08/2005 | US20050196434 Pharmaceutical composition and method for the transdermal delivery of magnesium |
| 09/08/2005 | US20050196423 Novel tissue engineered scaffolds derived from copper capillary alginate gels |
| 09/08/2005 | US20050196418 Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| 09/08/2005 | US20050196387 Chondrocytes expressing type II collagen; obtained from human cadavers and grown in vitro; injected into degenerative disc through an aperture or incision, closed with suture or biocompatible glue; harvest from hyaline cartilage of nose, ears, trachea, larynx, articular, costal, epiphyseal plate |
| 09/08/2005 | US20050196386 Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses |
| 09/08/2005 | US20050196382 Administering an oligonucleotide at least 10 nucleotides in length, whose antiviral activity occurs principally by a non-sequence complementary mode of action; especially for the prophylaxis treatment of cancer caused by oncoviruses |
| 09/08/2005 | US20050196379 Combination therapies with L-FMAU for the treatment of hepatitis B virus infection |
| 09/08/2005 | US20050196377 Covalent binding of a hydrogel to an extracellular matrix; primed extracellular matrix comprises tyrosyl radicals, polymerizable agent is an acrylate; tissue repair, delivery of drugs or cells |
| 09/08/2005 | US20050196374 Defecation deodorant |
| 09/08/2005 | US20050196346 Micronized or spray dried solid active ingredient (oxitropium or tiotropium salts which are soluble in water), and coating consisting of fatty acid, alcohol derivative, and poloxamer |
| 09/08/2005 | DE10361813A1 Using hematopoietic growth factors for structural regeneration of tissue, useful e.g. for treating liver damage and wounds |
| 09/07/2005 | EP1571158A2 Globular assembly of amyloid beta protein and uses thereof |
| 09/07/2005 | EP1571145A1 Substituted piperidine compounds for use as H3 histamine receptor antagonists |
| 09/07/2005 | EP1570861A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
| 09/07/2005 | EP1570859A2 Improved treatment of neovascularization |
| 09/07/2005 | EP1570752A1 Verwendung von ungesättigten Fettsäuren zur Verringerung des Appetits oder der Essensaufnahme |
| 09/07/2005 | EP1569723A2 Nucleotide based medicament and method of use for treatment of conditions in humans |
| 09/07/2005 | EP1569682A2 Combination treatment using exendin-4 and thiazolidinediones |
| 09/07/2005 | EP1569659A2 Dioxolane thymine and combinations for use against 3tc/ azt resistant strains of hiv |
| 09/07/2005 | EP1569658A2 Treatment of ebv and khsv infection and associated abnormal cellular proliferation |
| 09/07/2005 | EP1569657A1 Use of amphiphilic lipids for the preparation of a pharmaceutical composition for reducing tumor metastasis |
| 09/07/2005 | EP1569656A2 Phosphoantigens for regulating an immune response |
| 09/07/2005 | EP1569655A1 Use of selective progesterone receptor modulators for the treatment of androgen deficiency |
| 09/07/2005 | EP1569654A1 Use of devazepide in combination with an opioid analgesic for potentiating the effect of the analgesic |
| 09/07/2005 | EP1569640A2 Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
| 09/07/2005 | EP1569630A1 Methods for preventing phototoxic damage during photodynamic therapy |
| 09/07/2005 | EP1569617A1 Water stabilized medicinal aerosol formulation related applications |
| 09/07/2005 | EP1366039B1 Piperazinylcarbonylquinolines and -isoquinolines |
| 09/07/2005 | EP1333824B1 Treatment of sexual dysfunction with bombesin receptor antagonists |
| 09/07/2005 | EP1196195B1 Use of a fatty acid derivate in nasogastric enteral formulations |
| 09/07/2005 | EP1140026B1 Biodegradble polymer encapsulated serotonin receptor antagonist and method for preparing the same |
| 09/07/2005 | EP1025237B1 Human checkpoint kinase, hcds1, compositions and methods |
| 09/07/2005 | EP0731694B2 Opioid formulations for treating pain |
| 09/07/2005 | CN1666105A Oncolytic viruses as phenotyping agents for neoplasms |
| 09/07/2005 | CN1665933A Immunoconjugates for the treatment of tumours |
| 09/07/2005 | CN1665817A Process for preparing certain pyrrolotriazine compounds |
| 09/07/2005 | CN1665815A Novel tetracyclo-aryl-carbonyl indoles used as therapeutical agents with 5-hydroxy-tryptamine receptor affinity, their preparation process and pharmaceutical compounds containing same |
| 09/07/2005 | CN1665812A Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity |
| 09/07/2005 | CN1665811A Carbamate-substituted pyrazolopyridines |
| 09/07/2005 | CN1665566A Methods and compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium c |
| 09/07/2005 | CN1665554A Compounds and method for coating surfaces in a haemocompatible manner |